Comparative Pharmacology
Head-to-head clinical analysis: DITROPAN versus TOLTERODINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DITROPAN versus TOLTERODINE.
DITROPAN vs TOLTERODINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antimuscarinic/anticholinergic agent; competitively inhibits acetylcholine at muscarinic receptors, decreasing smooth muscle tone in the bladder.
Competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3, M4, M5), with selectivity for the M3 receptor subtype involved in detrusor muscle contraction, reducing bladder smooth muscle contractility and increasing bladder capacity.
5 mg orally 2-3 times daily. Maximum 5 mg 4 times daily. Immediate-release formulation.
2 mg PO twice daily; may reduce to 1 mg twice daily if tolerated.
None Documented
None Documented
Terminal elimination half-life of oxybutynin is approximately 2-3 hours, while its active metabolite desethyloxybutynin has a half-life of about 2-4 hours. Clinical context: Despite short half-life, extended-release formulations allow once-daily dosing.
Clinical Note
moderateTolterodine + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Tolterodine."
Clinical Note
moderateTolterodine + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Tolterodine."
Clinical Note
moderateTolterodine + Fluconazole
"The metabolism of Fluconazole can be decreased when combined with Tolterodine."
Clinical Note
moderateTolterodine + Clotrimazole
Terminal elimination half-life is 2-4 hours in extensive CYP2D6 metabolizers; increased to 4-10 hours in poor metabolizers or with CYP3A4 inhibitors.
Renal excretion accounts for approximately 60-80% of elimination, with about 10% as unchanged drug and the rest as metabolites (primarily desethyloxybutynin). Fecal elimination is minimal (<1%).
Primarily hepatic metabolism via CYP2D6 and CYP3A4; renal excretion accounts for <5% of unchanged drug; ~80% excreted in urine as metabolites, ~20% in feces.
Category C
Category A/B
Anticholinergic
Anticholinergic
"The metabolism of Clotrimazole can be decreased when combined with Tolterodine."